WO1990009162A3 - Anaphylatoxin-receptor ligands - Google Patents

Anaphylatoxin-receptor ligands Download PDF

Info

Publication number
WO1990009162A3
WO1990009162A3 PCT/US1990/000296 US9000296W WO9009162A3 WO 1990009162 A3 WO1990009162 A3 WO 1990009162A3 US 9000296 W US9000296 W US 9000296W WO 9009162 A3 WO9009162 A3 WO 9009162A3
Authority
WO
WIPO (PCT)
Prior art keywords
anaphylatoxin
receptor ligands
oligopeptide
compounds
ligands
Prior art date
Application number
PCT/US1990/000296
Other languages
French (fr)
Other versions
WO1990009162A2 (en
Inventor
Megumi Kawai
Yat Sun Or
Paul E Wiedeman
Jay R Luly
Mikel P Moyer
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of WO1990009162A2 publication Critical patent/WO1990009162A2/en
Publication of WO1990009162A3 publication Critical patent/WO1990009162A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Oligopeptide compounds or oligopeptide analogue compounds of the formula A-B-D-E-G-J-L-M-Q-T are ligands for the anaphylatoxin receptor and are useful in the treatment of inflammatory disease states. Also disclosed are anaphylatoxin receptor ligand compositions and a method for modulating anaphylatoxin activity.
PCT/US1990/000296 1989-01-31 1990-01-16 Anaphylatoxin-receptor ligands WO1990009162A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30469389A 1989-01-31 1989-01-31
US304,693 1989-01-31

Publications (2)

Publication Number Publication Date
WO1990009162A2 WO1990009162A2 (en) 1990-08-23
WO1990009162A3 true WO1990009162A3 (en) 1990-11-29

Family

ID=23177579

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/000296 WO1990009162A2 (en) 1989-01-31 1990-01-16 Anaphylatoxin-receptor ligands

Country Status (5)

Country Link
EP (1) EP0456758A4 (en)
JP (1) JPH04503073A (en)
CA (1) CA2045578A1 (en)
GR (1) GR900100052A (en)
WO (1) WO1990009162A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5386011A (en) * 1990-12-27 1995-01-31 Abbott Laboratories Hexapeptide anaphylatoxin-receptor ligands
US5387671A (en) * 1990-12-27 1995-02-07 Abbott Laboratories Hexa- and heptapeptide anaphylatoxin-receptor ligands
US5190922A (en) * 1991-06-04 1993-03-02 Abbott Laboratories Terminally modified tri-, tetra- and pentapeptide anaphylatoxin receptor ligands
WO1994007518A1 (en) * 1992-09-25 1994-04-14 Abbott Laboratories Anaphylatoxin receptor ligands containing lipophilic residues
US5807824A (en) * 1993-12-06 1998-09-15 Ciba-Geigy Corporation C5A receptor antagonists having substantially no agonist activity
US5837499A (en) * 1993-12-06 1998-11-17 Ciba-Geigy Corporation DNA encoding C5A receptor antagonists having substantially no agonist activity and methods of expressing same
US5614370A (en) * 1994-03-18 1997-03-25 Merck & Co., Inc. Assay to identify human C5a antagonists and agonists
US6057294A (en) * 1995-01-16 2000-05-02 Northern Sydney Area Health Service Of Pacific Highway Peptide
SE9603461D0 (en) * 1996-09-23 1996-09-23 Astra Ab New compounds
SE9603462D0 (en) * 1996-09-23 1996-09-23 Astra Ab New compounds
SE9603468D0 (en) * 1996-09-23 1996-09-23 Astra Ab New compounds
US6998106B1 (en) * 1998-12-01 2006-02-14 Duke University Radioconjugation of internalizing antibodies
TW200502221A (en) 2002-10-03 2005-01-16 Astrazeneca Ab Novel lactams and uses thereof
WO2004080983A1 (en) * 2003-03-14 2004-09-23 Astrazeneca Ab Novel lactams and uses thereof
EP1498422A1 (en) * 2003-07-17 2005-01-19 Jerini AG C5a Receptor Antagonists
RU2346943C2 (en) * 2003-10-24 2009-02-20 Авентис Фармасьютикалз Инк. New compounds and compositions for cathepsin inhibition
JP2008526915A (en) * 2005-01-17 2008-07-24 イエリニ・アクチェンゲゼルシャフト C5a receptor antagonist
EP1739078A1 (en) 2005-05-30 2007-01-03 Jerini AG Antagonists of C5a-receptor
EP2468295A1 (en) 2010-12-21 2012-06-27 Affiris AG Vaccines based on peptides of the complement protein C5a
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
CN103599523B (en) * 2013-11-25 2016-08-17 中国人民解放军第二军医大学 Pentapeptide metabolite application in preparing anti-inflammatory drug
US11918624B2 (en) 2020-06-10 2024-03-05 Kelsius Laboratories LLC Therapeutic composition for use in the treatment of COVID-19 and other cytokine storm associated disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692511A (en) * 1984-07-03 1987-09-08 Immunetech Pharmaceuticals Peptide antagonists for the C5a anaphylatoxin
CA1290097C (en) * 1985-07-24 1991-10-01 Merck & Co., Inc. Peptide enzyme inhibitors

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Federation Proceedings, Vol. 41, No. 14, December 1982, W. WEIGLE et al. Modulation of the Immune Response by Anaphylatoxin in the Microenvironment of the Interacting Cells", pages 3099-3103, see the entire document. *
Federation Proceedings, Vol. 43, No. 40, July 1984, E. MORGAN et al, "Anaphylatoxi-mediated Regulation of Human and Murine Immune Responses, see entire document, pages 2543-2547. *
J. Exp. med., Vol. 155, May 1982, E. MORGAN et al. "Anaphylatoxin-mediated Regulation of the Immune Response", pages 1412-1426, see the entire document. *
Proc. Natl. Acad. Sci. USA, Vol. 75, No. 8, August 1978, CHENOWETH et al., "Demonstration of Specific C5A Receptor on Intact Human Polymorphonuclear Leukocytes", pages 3943-3947, see the entire document. *
See also references of EP0456758A4 *
Springer Seminars in Immunopathology Vol. 7, 1984. T. HUGLI, "Structure and Function of the Anaphylatoxins", pages 193-219, see the entire document. *
The Journal of Biological Chemistry, Vol. 260, No. 12, 25 June 1985, T. ROLLINS et al. "Identification of the Polymorphonuclear Leukocyte C5a Receptor" pages 7157-7160, see the entire document. *
The Journal of Immunology, Vol. 120, No. 1, January 1978, H. FERNANDEZ et al., "Chemotactic response to human C3a and C5a anaphylatoxins", pages 109-115, see entire document. *

Also Published As

Publication number Publication date
EP0456758A1 (en) 1991-11-21
EP0456758A4 (en) 1992-07-08
JPH04503073A (en) 1992-06-04
WO1990009162A2 (en) 1990-08-23
GR900100052A (en) 1991-06-07
CA2045578A1 (en) 1990-08-01

Similar Documents

Publication Publication Date Title
WO1990009162A3 (en) Anaphylatoxin-receptor ligands
EP0564588A4 (en) Hexa- and heptapeptide anaphylatoxin-receptor ligands
CA2078996A1 (en) A bifunctional dtpa-type ligand
EP0604908A3 (en) Metallocene compounds having ligands of fluorenylic type.
AU617452B2 (en) The use of a composition for the surface treatment of soil
NO900830D0 (en) PROCEDURE FOR THE PREPARATION OF PIPERIDE COMPOUNDS.
AU7360887A (en) Pharmacologically active 1,5-diarly-3-substituted- pyrazoles and method for synthesizing the same
DE69114006D1 (en) COMPOSITIONS AND METHODS FOR THE CONTROLLED RELEASE OF SOLUBLE ACTIVE SUBSTANCES.
NO890269D0 (en) PROCEDURE FOR THE PREPARATION OF 1,4-DISUBSTITUTED-PIPERIDINYL COMPOUNDS.
AU631169B2 (en) Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
AU8937491A (en) Aryl and heteroaryl compounds having anti-retrovirus activity
DE69432413D1 (en) TREATMENT OF DEGENERATIVE VESSEL DISEASES BY MODULATING THE ENDOGENIC NITROGEN PRODUCTION OR ACTIVITY
NO895236L (en) PROCEDURE FOR PREPARING ISOTIOCYANATO-FUNCTIONALIZED METAL COMPLEXES.
AU5116590A (en) N-containing heterocyclic compounds, processes for the preparation thereof and composition comprising the same
NO892561D0 (en) PROCEDURE FOR THE MANUFACTURING OF BINDING AGENTS.
DE68911776D1 (en) Conjugated oxybutenolides for the treatment of ulcers.
NO903666L (en) PROCEDURE FOR THE PREPARATION OF PYRROLOKINOL COMPOUNDS.
NO931897D0 (en) PROCEDURE FOR PREPARING 2,3-HYDROXYMETHYL-CYCLOBUTANOL
NO891706L (en) PROCEDURE FOR THE PREPARATION OF CYCLEDDEXTRINE COMPLEXES OF 5-AMINO-HEXA HYDROPYRIMIDE COMPOUNDS.
NO904535L (en) PROCEDURE FOR THE PREPARATION OF PHENOXY-HETEROCYCLIC COMPOUNDS.
EP0475272A3 (en) Process for the preparation of 2,3,5-trimethyl-p-benzoquinone
EP0331105A3 (en) 1,2-hydroxy phosphonates and derivatives thereof
EP0402160A3 (en) Amine-alkylborane derivatives and methods
IL84433A0 (en) Safened sorptive granular pesticide-resin compositions for controlling soil borne pests and process for the preparation thereof
NO891376D0 (en) PROCEDURE FOR MANUFACTURING BLOOD PLATE ACTIVATING FACTORS.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1990903567

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1990903567

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1990903567

Country of ref document: EP